Filing Details

Accession Number:
0001179110-13-017896
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-12-13 16:55:07
Reporting Period:
2013-12-11
Filing Date:
2013-12-13
Accepted Time:
2013-12-13 16:55:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1145460 Alere Inc. ALR In Vitro & In Vivo Diagnostic Substances (2835) 043565120
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1571532 Kate Torchilin 51 Sawyer Road, Suite 200
Waltham MA 02453
Vp, Connected Health No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-12-11 10,000 $26.06 10,000 No 4 M Direct
Common Stock Disposition 2013-12-11 7,972 $33.73 2,028 No 4 S Direct
Common Stock Acquisiton 2013-12-11 675 $25.43 2,703 No 4 M Direct
Common Stock Disposition 2013-12-11 575 $33.73 2,128 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2013-12-11 10,000 $0.00 10,000 $26.06
Common Stock Employee Stock Option (Right to Buy) Disposition 2013-12-11 675 $0.00 675 $25.43
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2021-10-31 No 4 M Direct
0 2022-02-28 No 4 M Direct
Footnotes
  1. This price represents the average purchase price for 28 separate transactions reported on this line. The price of the transactions reported on this line range from $33.70 to $33.78. The reporting person hereby undertakes to provide upon request to the SEC, the issuer or any stockholder of the issuer the full information regarding the number of shares and prices at which the transaction was effected.
  2. These options became exercisable in four equal annual installments beginning 10/31/2012.
  3. These options became exercisable in four equal annual installments beginning 2/28/2013.
  4. This derivative security does not have a price.
  5. Represents sell to cover exercise of stock options.